Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Life expectancy for multiple myeloma patients has increased since the introduction of autologous stem cell transplantation and novel agents. While positive, longer life expectancy also relates to greater risk of second primary malignancies. This summary reviews current information about possible host-, disease-, and treatment-related risk factors for the development of second primary malignancies. Provided are practical recommendations to assist physicians.


P. Musto K. C. Anderson M. Attal P. G. Richardson A. Badros J. Hou R. Comenzo J. Du B. G. M. Durie J. San Miguel H. Einsele W. M. Chen L. Garderet G. Pietrantuono J. Hillengass R. A. Kyle P. Moreau J. J. Lahuerta O. Landgren H. Ludwig A. Larocca A. Mahindra M. Cavo A. Mazumder P. L. McCarthy A. Nouel S. V. Rajkumar A. Reiman E. R. Serra O. Sezer E. Terpos I. Turesson S. Usmani B. M. Weiss A. Palumbo on behalf of the International Myeloma Working Group

Learn more at:

Annals of Oncology, Volume 28, Issue 2, 1 February 2017, Pages 228–245,

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.